Virpax Historical Balance Sheet

VRPX Stock

USD 0.46 0.02 4.17%

Trend analysis of Virpax Pharmaceuticals balance sheet accounts such as Total Assets of 12.7 M, Short Long Term Debt Total of 1.2 M, Other Current Liabilities of 8.1 M or Total Current Liabilities of 8.1 M provides information on Virpax Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Virpax Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Virpax Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Virpax Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Virpax Pharmaceuticals is a good buy for the upcoming year.

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Virpax Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more information on how to buy Virpax Stock please use our How to Invest in Virpax Pharmaceuticals guide.

About Virpax Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Virpax Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Virpax Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Virpax Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Virpax currently owns. An asset can also be divided into two categories, current and non-current.

Virpax Pharmaceuticals Balance Sheet Chart

At this time, Virpax Pharmaceuticals' Total Current Assets are fairly stable compared to the past year. Short Term Debt is likely to rise to about 846.5 K in 2024, whereas Short and Long Term Debt Total is likely to drop slightly above 1.2 M in 2024.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities Common Stock Shares Outstanding Other Current Assets

Total Assets

Total assets refers to the total amount of Virpax Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Virpax Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Virpax Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Virpax Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Other Current Assets

Assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories.

Most accounts from Virpax Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Virpax Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Virpax Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more information on how to buy Virpax Stock please use our How to Invest in Virpax Pharmaceuticals guide.At this time, Virpax Pharmaceuticals' Total Current Assets are fairly stable compared to the past year. Short Term Debt is likely to rise to about 846.5 K in 2024, whereas Short and Long Term Debt Total is likely to drop slightly above 1.2 M in 2024.

	2023	2024 (projected)
Short and Long Term Debt Total	1.8M	1.2M
Total Assets	9.6M	12.7M

Short Long Term Debt Total Total Assets

Virpax Pharmaceuticals balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Short Long Term Debt	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt	Common Stock	Current Deferred Revenue	Inventory
Total Assets		0.64	0.37	0.3	0.97	0.79	-1.0	-0.56	0.49	1.0	1.0	0.45	-0.56	-0.65	0.97	0.85	0.26	0.96	0.02	1.0	0.79	0.97	0.02	0.79	-0.73	-0.21
Short Long Term Debt Total	0.64		0.71	0.71	0.49	0.73	-0.62	-0.76	0.4	0.64	0.64	0.82	-0.96	-0.25	0.56	0.82	0.83	0.5	0.39	0.64	0.41	0.5	0.39	0.41	-0.91	-0.38
Other Current Liab	0.37	0.71		0.99	0.12	0.81	-0.34	-0.94	-0.08	0.37	0.37	0.95	-0.67	-0.49	0.29	0.68	0.86	0.11	0.33	0.37	-0.11	0.13	0.33	-0.11	-0.73	-0.9
Total Current Liabilities	0.3	0.71	0.99		0.06	0.76	-0.28	-0.91	-0.14	0.31	0.31	0.94	-0.69	-0.4	0.23	0.63	0.88	0.05	0.41	0.3	-0.17	0.06	0.41	-0.17	-0.7	-0.89
Total Stockholder Equity	0.97	0.49	0.12	0.06		0.63	-0.97	-0.35	0.55	0.97	0.97	0.24	-0.4	-0.58	0.96	0.74	0.06	1.0	-0.09	0.97	0.88	1.0	-0.09	0.88	-0.58	0.03
Net Tangible Assets	0.79	0.73	0.81	0.76	0.63		-0.78	-0.94	0.24	0.79	0.79	0.82	-0.63	-0.8	0.69	0.95	0.63	0.61	0.16	0.79	0.41	0.63	0.16	0.41	-0.8	-0.68
Net Debt	-1.0	-0.62	-0.34	-0.28	-0.97	-0.78		0.55	-0.51	-1.0	-1.0	-0.44	0.53	0.66	-0.97	-0.86	-0.24	-0.97	0.01	-1.0	-0.81	-0.97	0.01	-0.81	0.71	0.18
Retained Earnings	-0.56	-0.76	-0.94	-0.91	-0.35	-0.94	0.55		-0.15	-0.57	-0.57	-0.92	0.68	0.67	-0.44	-0.87	-0.8	-0.34	-0.24	-0.56	-0.18	-0.35	-0.24	-0.18	0.8	0.78
Accounts Payable	0.49	0.4	-0.08	-0.14	0.55	0.24	-0.51	-0.15		0.5	0.5	-0.01	-0.33	-0.21	0.37	0.43	0.03	0.56	-0.31	0.49	0.83	0.56	-0.31	0.83	-0.55	0.35
Cash	1.0	0.64	0.37	0.31	0.97	0.79	-1.0	-0.57	0.5		1.0	0.45	-0.56	-0.65	0.97	0.86	0.26	0.96	0.02	1.0	0.8	0.97	0.02	0.8	-0.73	-0.21
Cash And Short Term Investments	1.0	0.64	0.37	0.31	0.97	0.79	-1.0	-0.57	0.5	1.0		0.45	-0.56	-0.65	0.97	0.86	0.26	0.96	0.02	1.0	0.8	0.97	0.02	0.8	-0.73	-0.21
Common Stock Total Equity	0.45	0.82	0.95	0.94	0.24	0.82	-0.44	-0.92	-0.01	0.45	0.45		-0.73	-0.48	0.38	0.78	0.95	0.23	0.29	0.45	0.0	0.24	0.29	0.0	-0.78	-0.73
Common Stock Shares Outstanding	-0.56	-0.96	-0.67	-0.69	-0.4	-0.63	0.53	0.68	-0.33	-0.56	-0.56	-0.73		0.06	-0.49	-0.68	-0.75	-0.42	-0.59	-0.55	-0.35	-0.41	-0.59	-0.35	0.83	0.4
Non Current Liabilities Total	-0.65	-0.25	-0.49	-0.4	-0.58	-0.8	0.66	0.67	-0.21	-0.65	-0.65	-0.48	0.06		-0.57	-0.73	-0.23	-0.55	0.38	-0.65	-0.38	-0.57	0.38	-0.38	0.48	0.48
Other Current Assets	0.97	0.56	0.29	0.23	0.96	0.69	-0.97	-0.44	0.37	0.97	0.97	0.38	-0.49	-0.57		0.75	0.18	0.96	0.01	0.97	0.72	0.96	0.01	0.72	-0.64	-0.17
Other Stockholder Equity	0.85	0.82	0.68	0.63	0.74	0.95	-0.86	-0.87	0.43	0.86	0.86	0.78	-0.68	-0.73	0.75		0.64	0.73	0.09	0.85	0.6	0.74	0.09	0.6	-0.85	-0.43
Total Liab	0.26	0.83	0.86	0.88	0.06	0.63	-0.24	-0.8	0.03	0.26	0.26	0.95	-0.75	-0.23	0.18	0.64		0.05	0.31	0.25	-0.09	0.06	0.31	-0.09	-0.74	-0.58
Net Invested Capital	0.96	0.5	0.11	0.05	1.0	0.61	-0.97	-0.34	0.56	0.96	0.96	0.23	-0.42	-0.55	0.96	0.73	0.05		-0.08	0.96	0.89	1.0	-0.08	0.89	-0.58	0.05
Short Long Term Debt	0.02	0.39	0.33	0.41	-0.09	0.16	0.01	-0.24	-0.31	0.02	0.02	0.29	-0.59	0.38	0.01	0.09	0.31	-0.08		0.02	-0.14	-0.09	1.0	-0.14	-0.08	-0.33
Total Current Assets	1.0	0.64	0.37	0.3	0.97	0.79	-1.0	-0.56	0.49	1.0	1.0	0.45	-0.55	-0.65	0.97	0.85	0.25	0.96	0.02		0.79	0.97	0.02	0.79	-0.72	-0.21
Capital Stock	0.79	0.41	-0.11	-0.17	0.88	0.41	-0.81	-0.18	0.83	0.8	0.8	0.0	-0.35	-0.38	0.72	0.6	-0.09	0.89	-0.14	0.79		0.88	-0.14	1.0	-0.48	0.32
Net Working Capital	0.97	0.5	0.13	0.06	1.0	0.63	-0.97	-0.35	0.56	0.97	0.97	0.24	-0.41	-0.57	0.96	0.74	0.06	1.0	-0.09	0.97	0.88		-0.09	0.88	-0.58	0.03
Short Term Debt	0.02	0.39	0.33	0.41	-0.09	0.16	0.01	-0.24	-0.31	0.02	0.02	0.29	-0.59	0.38	0.01	0.09	0.31	-0.08	1.0	0.02	-0.14	-0.09		-0.14	-0.08	-0.33
Common Stock	0.79	0.41	-0.11	-0.17	0.88	0.41	-0.81	-0.18	0.83	0.8	0.8	0.0	-0.35	-0.38	0.72	0.6	-0.09	0.89	-0.14	0.79	1.0	0.88	-0.14		-0.48	0.32
Current Deferred Revenue	-0.73	-0.91	-0.73	-0.7	-0.58	-0.8	0.71	0.8	-0.55	-0.73	-0.73	-0.78	0.83	0.48	-0.64	-0.85	-0.74	-0.58	-0.08	-0.72	-0.48	-0.58	-0.08	-0.48		0.45
Inventory	-0.21	-0.38	-0.9	-0.89	0.03	-0.68	0.18	0.78	0.35	-0.21	-0.21	-0.73	0.4	0.48	-0.17	-0.43	-0.58	0.05	-0.33	-0.21	0.32	0.03	-0.33	0.32	0.45

Click cells to compare fundamentals

Virpax Pharmaceuticals Account Relationship Matchups

Virpax Pharmaceuticals balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	46.7K	465.4K	39.6M	19.7M	9.6M	12.7M
Other Current Liab	1.5M	3.1M	2.1M	3.1M	7.7M	8.1M
Total Current Liabilities	2.8M	3.7M	2.1M	3.1M	7.7M	8.1M
Total Stockholder Equity	(2.7M)	(4.2M)	37.5M	16.6M	1.9M	1.8M
Net Debt	1.2M	1.5M	(36.8M)	(19.0M)	(9.1M)	(9.6M)
Retained Earnings	(6.3M)	(10.6M)	(22.7M)	(44.4M)	(59.5M)	(56.6M)
Accounts Payable	3.5	22.1K	19.8K	37.6K	18.46	17.54
Cash	41.5K	54.8K	36.8M	19.0M	9.1M	11.9M
Cash And Short Term Investments	41.5K	54.8K	36.8M	19.0M	9.1M	11.9M
Common Stock Shares Outstanding	521.5K	494.5K	1.2M	1.2M	1.2M	1.3M
Liabilities And Stockholders Equity	46.7K	465.4K	39.6M	19.7M	9.6M	12.7M
Other Current Assets	467.0	18.3K	2.7M	678.4K	486.8K	720.0K
Other Stockholder Equity	3.6M	6.4M	60.2M	60.9M	61.5M	35.6M
Total Liab	2.8M	4.7M	2.1M	3.1M	7.7M	4.0M
Net Invested Capital	(1.5M)	(2.7M)	37.5M	16.6M	1.9M	1.8M
Total Current Assets	46.7K	73.1K	39.6M	19.7M	9.6M	12.7M
Net Working Capital	(2.7M)	(3.6M)	37.5M	16.6M	1.9M	1.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Virpax Stock Analysis

When running Virpax Pharmaceuticals' price analysis, check to measure Virpax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virpax Pharmaceuticals is operating at the current time. Most of Virpax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Virpax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virpax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Virpax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Virpax Historical Balance Sheet

About Virpax Balance Sheet Analysis

Virpax Pharmaceuticals Balance Sheet Chart

Total Assets

Total Current Liabilities

Common Stock Shares Outstanding

Other Current Assets

Virpax Pharmaceuticals balance sheet Correlations

Virpax Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Virpax Pharmaceuticals balance sheet Accounts

Also Currently Popular

Additional Tools for Virpax Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Stockholder Equity
Net Working Capital	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Cash

Total Current Assets	- 1.0	Net Debt
Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Net Debt	- 1.0	Total Assets
Net Working Capital	- 0.97	Net Debt
Net Invested Capital	- 0.97	Net Debt